Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC2248 | Thalidomide |
| Teratogen, sedative-hypnotic with inherent anti-inflammatory properties. A selective inhibitor of tumor necrosis factor α (TNF-α) synthesis. | |
| BCC2257 | TW-37 |
| Bcl-2 inhibitor (Ki values are 0.29 μM and 1.11 μM for Bcl-2 and Bcl-XL respectively). Inhibits the angiogenic potential of endothelial cells in vitro. Induces S-phase arrest and apoptosis in pancreatic cancer cell lines; also inhibits the activation of Notch-1 and Jagged-1 in vitro and in vivo. | |
| BCC2260 | GW9662 |
| Selective PPARγ antagonist (IC50 values are 3.3, 32 and 2000 nM for PPARγ, PPARα and PPARδ respectively). Blocks the inhibition of osteoclast formation induced by IL-4 in the low micromolar range (1-2 μM), therefore is more potent than BADGE. Anticancer, inhibits growth of human mammary tumor cell lines. | |
| BCC2261 | T0070907 |
| Potent and selective PPARγ antagonist (IC50 = 1 nM). Displays > 800-fold selectivity for PPARγ over PPARα and PPARδ. Blocks transcriptional activity of PPARγ in vitro and inhibits rosiglitazone-induced adipogenesis. | |
| BCC2263 | GSK3787 |
| Potent and selective peroxisome proliferator-activated receptor δ (PPARδ) antagonist (pIC50 = 6.6). Displays no measurable affinity for PPARα or PPARγ in vitro (pIC50< 5). | |
| BCC2264 | Rosiglitazone |
| Potent and selective PPARγ agonist (EC50 = 60 nM); exhibits no activity at PPARα and PPARβ. Promotes differentiation of pluripotent C3H10T1/2 stem cells into adipocytes. Exhibits antihyperglycemic activity in diabetic ob/ob mouse model. Antidiabetic agent. | |
| BCC2265 | WY-14643 (Pirinixic Acid) |
| Selective PPARα agonist (EC50 values are 0.63, 32 and > 100 μM at PPARα, PPARγ and PPARδ respectively). Negatively inhibits NF-κB transcriptional activity and decreases the inflammatory response in vitro and in vivo. | |
| BCC2267 | GW0742 |
| Potent and highly selective PPARδ agonist. EC50 values are 0.001, 1.1 and 2 μM for transactivation of human PPARδ, -α, and -γ receptors respectively. Neuroprotective in rat cerebellar granule neuronal cultures after brief (12-hour) exposure but exhibits inherent toxicity after prolonged (48-hour) incubation. Increases rate of fatty acid oxidation and protects against ischemia/reperfusion injury in neonatal and adult cardiomyocytes. | |
